EFFECT OF LITHIUM THERAPY ON THYROID FUNCTION: A RETROSPECTIVE STUDY ON INDIAN PATIENTS by Srivastava, A.S. et al.
Indian J. Psychiat., 1993,35(2), 131-134 
EFFECT OF LITHIUM THERAPY ON THYROID FUNCTION: 
A RETROSPECTIVE STUDY ON INDIAN PATIENTS 
A.S.SRIVASTAVA, P.B.BEHERE, J.K.AGRAWAL 
SUMMARY 
Thirty patients with Bipolar affective disorder who were on Lithium therapy for 6 months to 24 months, were tested 
for any alterationin their thyroidfunction. Eight (26.67%) patients hadelevated serum TSHlevelandfour (13.33%) 
patients had decreased serum T4 level than the normal range. Serum T3, although showing a declining trend
 w<*s 
found within the normal range in all the patients. 
The chance discovery of lithium's psychoactive 
properties by the Australian psychiatrist, John Cade in 
1949 echoed the beginning of a new era in the treatment 
of mental disorders. Today, lithium is one of the major 
therapeutic appliances used by psychiatrists the worldover 
in the treatment of Manic Depressive Psychoses. It has 
established its efficacy as a prophylactic agent for prevent-
ing future manic and depressive relapses. Among the 
various side effects recognized during the course of 
lithium therapy, one of the major ones was the develop-
ment of various types of thyroid abnormal ities. Goiter was 
recognized first (Schou et al, 1968; Fieve & Platman, 
1968) followed by various reports of patients developing 
overt hypothyroidism (Wigger, 1968; Sedvall et al, 1968; 
Shopson et al, 1969) and hypothyroidism (Villeneuve et 
al, 1973). Reus et al (1979) reported hyperthyroidism and 
thyrotoxicosis following lithium therapy. Kuruvilla et al 
(1983) reported no change in thyroid function. 
Recently Bocchetta et al (1991) reported visible and/or 
palpable goiter in 51% and subclinical hypothyroidism in 
19% of patients. They also reported thyroid antibodies in 
15% of lithium treated patients. The prevalence of specific 
antithyroid antibodies was higher in women and correlated 
positively with age and duration of lithium treatment. In 
another 2 year follow up study, Bocchetta et al (1992) 
observed that elevated thyroid stimulati ng hormone (TSH) 
concentrations were transitory in most patients except 
those with serum antithyroid antibodies. Those patients 
who initially had microsomal antibodies remained posi-
tive with an increase in titre in two-third of cases. They 
reported a higher risk of developing hypothyroidism in 
women, especially in presence of antibodies. 
Little work has been done in India to find out the effect 
of lithium therapy on thyroid function in Indian patients. 
Kuruvilla et al (1983) had conducted a study which did not 
reveal any change in thyroid function after long term 
lithium therapy. The present study was conducted at S.S. 
Hospital, attached to Department of Psychiatry, Institute 
ofMedical Sciences, Banaras Hindu University, Varanasi, 
India, with the following aims: 
1.To study the clinical effect of lithium therapy on thyroid 
function in case of major affective disorder (bipolar). 
2.To compare the effect of lithium therapy on thyroid 
function with age and sex matched controls of major 
affective disorder (bipolar) who were not on lithium 
therapy but were receiving other antipsychotic drugs. 
3.To find out correlation between duration of lithium 
therapy and serum T3.T4 & TSH levels. 
4.T0 find out correlation between dose of lithium and 
serum T3, T4 & TSH levels. 
5. To find out correlation between serum lithium levels 
and serum T3, T4 & TSH levels. 
METHOD 
The study was conducted over a period of one year 
(January to December 1988) and informed consent was 
taken in each case, explaining the nature of the test. Only 
patients with Major Affective Disorder (Bipolar) who 
fulfilled the diagnostic criteria according to DSM HI 
(American Psychiatric Association, 1980) were included 
in the study. Thirty patients who were only on prophylactic 
Lithium therapy for 6 months to 24 months and were 
euthymic for at least two months, were compared with age 
and sex matched controls. The controls consisted of 30 
patients with major affective disorder who were euthymic 
for at least two months and were on antipsychotic therapy 
but not on lithium. 
Patients with a history of any associated physical ill-
ness, history of irregular lithium therapy or havingstopped 
lithium at any time during their maintenance, serum 
lithium levels lower or higher than prophylactic range i.e. 
0.6 meq/L to 1.2 meq/L (Wolpert, 1980) were excluded 
from the study. Female patients were specially screened 
for pregnancy; those who were pregnant or who had 
amenorrhoea for more than 4 weeks were excluded from 
the study. A special precaution was taken for the history 
of intake of drugs which alter thyroid function e.g. 
thiocyanates and perchlorates, PAS, sulphonylureas, 
phenylbutazone, liquid I2, carbamazepine, steroids etc. 
Thorough physical examination with special reference 
to clinical assessment of the thyroid was done in each 
patient. Thyroid hormone profile of both study and control 
groups was assessed by measuring serum T3, T4 and TSH 
levels by Radioimmunoassay technique. The serum 
Lithium levels of patients in the study group were es-
timated by the method described by Amdisen (1967), 
using a digital flame and emission photometer. 
RESULTS 
Patients were between the ages of 21 and 50 (mean 34.4 
years); 50% between 31-40 years, 43.3% between 21-30 
and 6.7% between 41-50 years. There were 25 (83.3%) 
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men and 5 (16.7%) women. The majority of pa tients(SO%; 
M=43.3%; F=6.6%) were on I ithium therapy for more than 
6 to 12 months; Thirty percent were on lithium for 12 to 
18 months and twenty percent on lithium for 18 to 24 
months. The mean duration of lithium therapy was 14.17 
months. 
The largest group (50%; M=46.7%, F=3.3%) was 
formed by the patients who received 900 mg of lithium 
carbonate per day; 23.3% were on 600 mg, 16.7% on 750 
mg, 6.7% on 1050 mg and 3.3% received 1200 mg of 
lithium carbonate per day. Forty percent (M=30%, 
F=10%) patients were in the dose range of 600-750 
mg/day while 60% (M=53.3%, F=6.7%) were in the dose 
range of 700-1200 mg/day. The mean dose was 824 
mg/day. 
In the majority (40%) of the patients, serum level of 
lithium was 0.6 meq/L; it was 0.7 meq/L in 23.3%, 0.8 
meq/L in 26.7% and 0.9 meq/L in 10% of patients. Sixty 
three percent had serum lithium levels in the range of 
0.7-0.8 meq/L and 36.7% had between 0.8-0.9 meq/L. 
The estimation of thyroid hormone profile revealed 
decreased serum T4 levels in 4 (13.3%) patients and in-
creased serum TSH levels in 8 (26.7%) patients (Table 1). 
Although the value of serum T3 was within the normal 
range in all patients of the study group, it showed a 
TABLE 1 
Comparison of serum T4 and serum TSH levels in patients of 
study and control groups (based on standard laboratory values) 
Total 
No. 
Serum T 
WNR 
No. % 
Serum TSH 
<NR WNR >NR 
No. % No. % No. % 
Study 30 26 86.7 4 13.3 22 73.3 8 26.7 
Controls 30 30 100 - - 30 100 - -
[WNR: Within normal range; >NR: Higher than normal range; 
< NR: Lower than normal range 
Normal range: Serum T3:0.4 to 2 ng/ml 
SerumTSH:0.25to4milil.U/L 
Serum T4:6 to 14/ug % 
TABLE2 
Comparison of serum T
3, T* and TSH level in patients of study 
and control group (based on statistical analysis) 
Variable 
T
a 
(ng/ml) 
(ug%) 
TSH 
(m I.U/L) 
l
i
l
t
 0.9 ± 0.37 
(0.5 to 1.8) 
9.36 ±2.67 
(4 to 11.6) 
3.03 * 1 .96 
(0.28 to 7.4) 
f
l
i
t
 0.97 ±0.32 
(0.6 to 1.6) 
11.38 ±2.17 
(8 to 12.4) 
1.94 ±0.75 
(1.4 to 3.24) 
t 
0.78 
0.22 
2.81 
P 
>0.4 
>0.8 
* 
•Significant (p< 0.01) 
declining trend towards the lowerside of the normal range. 
On comparison, the difference between serum TSH levels 
in study group and control group was statistically sig-
nificant (Table 2). 
A positive correlation was found between the duration 
of lithium therapy and serum TSH level. The correlation 
coefficient between duration of lithium therapy and serum 
T3 and T4 levels was negative. Similarly, a positive cor-
relation was found between serum lithium and serum TSII 
whereas a negative correlation was found between serum 
lithium and serum T3 and T4. However, none of the 
correlation coefficients were statistically significant. 
DISCUSSION 
This study was conducted to find out the effect of 
lithium therapy on thyroid function. There was a male 
preponderance of 5:1 in the study group. Kuruvilla et al 
(1983) also reported a preponderance of males in their 
study (3:1). The majority of the patients (63.33%) were 
having Serum Lithium levels in the range of 0.6 to 0.7 
meq/L, mean being 0.7 meq/L. Thisis in concordance with 
the findings of Maarbjerg et al (1987) who reported 
average serum lithium of 0.69 meq/L. 
In earlier studies (Schou et al, 1968; Brownlie et al, 
1976) it was found that patients who were on lithium 
therapy developed altered thyroid functions. Goiter was 
reported by Schou et al (1968) while Brownlie etal (1976) 
reported 14 cases of hypothyroidism and 4 cases of 
thyrotoxicosis. None of the patients in the study group had 
any evidence of thyroidswelling or goiter. Other observers 
(Sedvall et al, 1969; Cooper et al, 1969; Myers et al, 1985) 
also have not reported development of goiter despite 
longterm lithium use. Any clinical evidence of hyper-
thyroidism or thyrotoxicosis was not found in any of the 
patients of the study group, although cases of 
thyrotoxicosis have also been reported during lithium 
therapy without an obvious reduction in the dosage or 
serum level of lithium (Rosser, 1976; Cubbett, 1967). 
The hormone profile of 8 patients (26.7%) of the study 
group revealed elevated serum TSH levels above the nor-
mal range (0.25 - 4 mlU/L). McLarz et al (1975), Emerson 
et al (1973) and Lazarus et al (1981) also reported eleva-
tion ofbasal TSH in 15.3% of patients on lithium therapy. 
Serum T4 was found to be reduced below the normal range 
(6-14 mg%) in 4 patients (13.3%). Reduction in serum T4 
values in patients on lithium has also been reported by 
Emerson et al (1973) and Hullin et al (1975). 
When serum T3, T4 and TSH levels were compared 
between patients in the study and control group, there was 
a decreasing trend in T3 and T4 towards the lower side of 
the normal range in patients of study group, although the 
difference was not statistically significant. The com-
parison of serum TSH level in patients of study and control 
groups showed an increasing trend towards the higher side 
of the normal range in study group and the difference was 
statistically significant. The comparison of serum T3, T4 
and TSH between male and female patients of study group 
did not show significant difference between male and 
female, although Crow et al (1973) reported that the 
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changes are more in females then males. 
Simple correlation coefficient (r) between the duration 
of lithium therapy and serum T3, T4 and TSH was found 
to be negative for serum T3 & T4 and positive for serum 
TSH. Similarly, simple correlation coefficient (r) between 
dose of lithium per day and serum T3, T4 and TSH showed 
a negative correlation between the dose of lithium and 
serum T3 & T4 and a positive correlation with serum TSH. 
The correlation coefficient between serum lithium and 
serum T3, T4 was negative while correlation coefficient 
between serum lithium and serum TSH was positive. The 
correlation of dose, duration and serum level of lithium 
with serum T3, T4 and TSH levels indicates that higher 
dose, longer duration and higher serum levels of lithium 
increase the probability of reduction of thyroid hormone 
status of patients on lithium. 
CONCLUSION 
Development of various types of thyroid abnormalities 
have been reported during the course of lithium therapy: 
goiter by Schou et al (1978), hypothyroidism by Wigger 
(1968), Sedvall et al, (1968) and hyperthyroidism and 
thyrotoxicosis by Reus et al (1979). Kuruvilla et al (1983) 
reported no change in thyroid function. The present study 
conducted on Indian patients, fulfilling DSM-1II criteria 
for Major Affective Disorder (bipolar) on prophylactic 
lithium therapy for 6 to 24 months revealed changes in the 
thyroid hormone profile of these patients. These changes 
are suggestive of increased serum TSH and decreased 
serum T3 and T4 levels in patients of lithium therapy, 
although no clinical evidence of hypothyroidism could be 
detected. 
If these patients are followed up for longer duration, it 
is quite likely that they may develop signs and symptoms 
of clinical hypothyroidism. This suggests that the thyroid 
hormone status must be screened at regular intervals in 
patients on lithium therapy. 
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